Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.

Background: Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe inflammatory demyelinating disease of the central nervous system that often causes disability. Based on evidence from prospective and retrospective studies, Rituximab (RTX) has been used as the first-line of therapy in NMOSD. Nevertheless, evidence of the impact of RTX on relapse rate and disability in Ecuadorian patients with NMOSD is lacking.

Correction to: Case series of Creutzfeldt-Jakob disease in a third-level hospital in Quito.

Following publication of the original article [1], Andrés Damián Ortega Heredia requested that his name be corrected from.

Case series of Creutzfeldt-Jakob disease in a third-level hospital in Quito.

Background: Creutzfeldt-Jakob disease is a rare and fatal neurodegenerative disorder that affects mammals and humans. The prevalence of this disease in the United States is 0.5 to 1 per million inhabitants.